The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS).

UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns Hopkins University (JHU) Autoimmunity Center of Excellence in actively dosing patients with foralumab, the first fully human anti-CD3 monoclonal antibody administered via the intranasal route. This novel, non-systemic approach is designed to engage regulatory T cells, promoting immune tolerance while minimising systemic immune suppression.

This blinded, placebo-controlled trial is expected to be completed by the end of 2025. Following the completion of the blinded phase, all participants—including those who initially received placebo—will have the opportunity to receive intranasal foralumab during a six-month open-label extension (OLE) phase. The OLE is designed to assess long-term safety and sustained benefit, of foralumab in the na-SPMS patient population. 

“We are excited to add UMass as a clinical site in our Phase II trial. The increasing number of premier institutions participating in our study reflects great enthusiasm within the scientific and medical communities for intranasal foralumab as a potential treatment for patients with non-active SPMS,” said William Clementi, Chief Development Officer of Tiziana Life Sciences. “We remain committed to advancing this important research as we work toward a much-needed new treatment for this underserved patient population. Intranasal dosing allows foralumab to be administered at home. Our hope is that this improves compliance and outcomes versus more commonly seen intravenous dosing which can be a burden on a patient population who suffer with fatigue, and who would normally need to attend a clinic.”

Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: “The initiation of dosing at UMass marks another significant step forward in our mission to bring foralumab to patients living with non-active SPMS. We are grateful for the dedication of our investigators and research teams across all sites, as well as the patients who are participating in this trial. We look forward to the completion of the study and the insights it will provide into the potential benefits of foralumab.”

Megan Thomas, Multimedia Editor, DDW